Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis.

Bhattarai A, Nakajima T, Sapkota S, Arisaka Y, Tokue A, Yonemoto Y, Tsushima Y.

Medicine (Baltimore). 2017 Jun;96(25):e7130. doi: 10.1097/MD.0000000000007130.

2.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.

3.

Fasciola Hepatica Mimicking Malignancy on 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.

Sürücü E, Demir Y, Dülger AC, Batur A, Ölmez Ş, Kitapçı MT.

Mol Imaging Radionucl Ther. 2016 Oct 5;25(3):143-146. doi: 10.4274/mirt.97759.

4.

18F-NaF Positive Bone Metastases of Non 18F-FDG Avid Mucinous Gastric Cancer.

Soydal Ç, Özkan E, Küçük ÖN, Kır MK.

Mol Imaging Radionucl Ther. 2015 Oct 5;24(3):132-4. doi: 10.4274/mirt.92400.

5.

Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.

Subramaniam RM, Shields AF, Sachedina A, Hanna L, Duan F, Siegel BA, Hillner BE.

Oncologist. 2016 Sep;21(9):1079-84. doi: 10.1634/theoncologist.2015-0364. Epub 2016 Jul 8.

6.

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer.

Zhang S, Li W, Liang F.

Oncotarget. 2016 Jul 26;7(30):48600-48606. doi: 10.18632/oncotarget.9375.

7.

PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.

Fischer BM, Siegel BA, Weber WA, von Bremen K, Beyer T, Kalemis A.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1749-52. doi: 10.1007/s00259-016-3414-5. Epub 2016 May 13. No abstract available.

8.

Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.

Capitanio S, Bongioanni F, Piccardo A, Campus C, Gonella R, Tixi L, Naseri M, Pennone M, Altrinetti V, Buschiazzo A, Bossert I, Fiz F, Bruno A, DeCensi A, Sambuceti G, Morbelli S.

World J Radiol. 2016 Feb 28;8(2):200-9. doi: 10.4329/wjr.v8.i2.200.

9.

Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.

Healy MA, Yin H, Reddy RM, Wong SL.

J Natl Cancer Inst. 2016 Feb 22;108(7). doi: 10.1093/jnci/djv429. Print 2016 Jul.

10.

The Utility of Molecular Imaging in Prostate Cancer.

Leiblich A, Stevens D, Sooriakumaran P.

Curr Urol Rep. 2016 Mar;17(3):26. doi: 10.1007/s11934-015-0573-z. Review.

11.

The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Robertson NL, Hricak H, Sonoda Y, Sosa RE, Benz M, Lyons G, Abu-Rustum NR, Sala E, Vargas HA.

Gynecol Oncol. 2016 Mar;140(3):420-4. doi: 10.1016/j.ygyno.2016.01.011. Epub 2016 Jan 11.

12.

Focal colorectal uptake in (18)FDG-PET/CT: maximum standard uptake value as a trigger in a semi-automated screening setting.

Luboldt W, Wiedemann B, Fischer S, Bodelle B, Luboldt HJ, Grünwald F, Vogl TJ.

Eur J Med Res. 2016 Jan 9;21:2. doi: 10.1186/s40001-016-0195-z.

13.

18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.

Spick C, Herrmann K, Czernin J.

J Nucl Med. 2016 Mar;57(3):420-30. doi: 10.2967/jnumed.115.158808. Epub 2016 Jan 7. Review.

14.

FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.

Petersen H, Holdgaard PC, Madsen PH, Knudsen LM, Gad D, Gravergaard AE, Rohde M, Godballe C, Engelmann BE, Bech K, Teilmann-Jørgensen D, Mogensen O, Karstoft J, Johansen J, Christensen JB, Johansen A, Høilund-Carlsen PF; PET/CT Task Force of the Region of Southern Denmark.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):695-706. doi: 10.1007/s00259-015-3217-0. Epub 2015 Oct 30.

15.

Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR.

Ladefoged CN, Hansen AE, Keller SH, Fischer BM, Rasmussen JH, Law I, Kjær A, Højgaard L, Lauze F, Beyer T, Andersen FL.

EJNMMI Phys. 2015 Dec;2(1):8. doi: 10.1186/s40658-015-0112-5. Epub 2015 Mar 11.

16.

(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.

You JJ, Cline KJ, Gu CS, Pritchard KI, Dayes IS, Gulenchyn KY, Inculet RI, Dhesy-Thind SK, Freeman MA, Chan AM, Julian JA, Levine MN.

Br J Cancer. 2015 May 26;112(11):1737-43. doi: 10.1038/bjc.2015.151. Epub 2015 May 5.

17.

Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.

Kubota K, Matsuno S, Morioka N, Adachi S, Koizumi M, Seto H, Kojo M, Nishioka S, Nishimura M, Yamamoto H.

Ann Nucl Med. 2015 Jun;29(5):431-41. doi: 10.1007/s12149-015-0963-9. Epub 2015 Mar 27.

18.

Dosimetry of patients submitted to cerebral PET/CT for the diagnosis of mild cognitive impairment.

Santana Pdo C, Mourão AP, de Oliveira PM, Bernardes FD, Mamede M, da Silva TA.

Radiol Bras. 2014 Nov-Dec;47(6):350-4. doi: 10.1590/0100-3984.2013.1800.

19.

Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany.

Bailey DL, Antoch G, Bartenstein P, Barthel H, Beer AJ, Bisdas S, Bluemke DA, Boellaard R, Claussen CD, Franzius C, Hacker M, Hricak H, la Fougère C, Gückel B, Nekolla SG, Pichler BJ, Purz S, Quick HH, Sabri O, Sattler B, Schäfer J, Schmidt H, van den Hoff J, Voss S, Weber W, Wehrl HF, Beyer T.

Mol Imaging Biol. 2015 Jun;17(3):297-312. doi: 10.1007/s11307-014-0818-0.

20.

Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.

Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.

PLoS One. 2014 Dec 17;9(12):e115127. doi: 10.1371/journal.pone.0115127. eCollection 2014.

Supplemental Content

Support Center